181 related articles for article (PubMed ID: 15793282)
21. Glucosamine for psoriasis?
McCarty MF
Med Hypotheses; 1997 May; 48(5):437-41. PubMed ID: 9185133
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of N-acetylglucosaminyltransferase-V by heparin-binding EGF-like growth factor induces keratinocyte proliferation and epidermal hyperplasia.
Kimura A; Terao M; Kato A; Hanafusa T; Murota H; Katayama I; Miyoshi E
Exp Dermatol; 2012 Jul; 21(7):515-9. PubMed ID: 22716246
[TBL] [Abstract][Full Text] [Related]
23. Antagonism of epidermal growth factor receptor tyrosine kinase ameliorates the psoriatic phenotype in organ-cultured skin.
Varani J; Lateef H; Fay K; Elder JT
Skin Pharmacol Physiol; 2005; 18(3):123-31. PubMed ID: 15897684
[TBL] [Abstract][Full Text] [Related]
24. Psoriasiform architecture of murine epidermis overlying human psoriatic dermis transplanted onto SCID mice.
Boehncke WH; Sterry W; Hainzl A; Scheffold W; Kaufmann R
Arch Dermatol Res; 1994; 286(6):325-30. PubMed ID: 7979548
[TBL] [Abstract][Full Text] [Related]
25. Tissue remodeling induced by hypersecreted epidermal growth factor and amphiregulin in the airway after an acute asthma attack.
Enomoto Y; Orihara K; Takamasu T; Matsuda A; Gon Y; Saito H; Ra C; Okayama Y
J Allergy Clin Immunol; 2009 Nov; 124(5):913-20.e1-7. PubMed ID: 19895983
[TBL] [Abstract][Full Text] [Related]
26. Phosphodiesterase 7A inhibitor ASB16165 impairs proliferation of keratinocytes in vitro and in vivo.
Goto M; Kadoshima-Yamaoka K; Murakawa M; Yoshioka R; Tanaka Y; Inoue H; Murafuji H; Kanki S; Hayashi Y; Nagahira K; Ogata A; Nakatsuka T; Fukuda Y
Eur J Pharmacol; 2010 May; 633(1-3):93-7. PubMed ID: 20132810
[TBL] [Abstract][Full Text] [Related]
27. IL-4 Downregulates IL-1β and IL-6 and Induces GATA3 in Psoriatic Epidermal Cells: Route of Action of a Th2 Cytokine.
Onderdijk AJ; Baerveldt EM; Kurek D; Kant M; Florencia EF; Debets R; Prens EP
J Immunol; 2015 Aug; 195(4):1744-52. PubMed ID: 26170379
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of keratin 17 expression with antisense and RNAi strategies: exploring novel therapy for psoriasis.
Chang T; Sun L; Wang Y; Wang D; Li W; Li C; Gao T; Liu Y; Wang G
Exp Dermatol; 2011 Jul; 20(7):555-60. PubMed ID: 21355890
[TBL] [Abstract][Full Text] [Related]
29. Amphiregulin expression in human mast cells and its effect on the primary human lung fibroblasts.
Wang SW; Oh CK; Cho SH; Hu G; Martin R; Demissie-Sanders S; Li K; Moyle M; Yao Z
J Allergy Clin Immunol; 2005 Feb; 115(2):287-94. PubMed ID: 15696083
[TBL] [Abstract][Full Text] [Related]
30. Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides.
Wraight CJ; White PJ; McKean SC; Fogarty RD; Venables DJ; Liepe IJ; Edmondson SR; Werther GA
Nat Biotechnol; 2000 May; 18(5):521-6. PubMed ID: 10802619
[TBL] [Abstract][Full Text] [Related]
31. Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes: induction of psoriasis by cells with natural killer receptors.
Gilhar A; Ullmann Y; Kerner H; Assy B; Shalaginov R; Serafimovich S; Kalish RS
J Invest Dermatol; 2002 Aug; 119(2):384-91. PubMed ID: 12190861
[TBL] [Abstract][Full Text] [Related]
32. Epidermal hyperplasia induced by Raf-MAPK signaling requires Stat3 activation.
Tarutani M; Nakajima K; Takaishi M; Ohko K; Sano S
J Dermatol Sci; 2013 Nov; 72(2):110-5. PubMed ID: 23870655
[TBL] [Abstract][Full Text] [Related]
33. Amphiregulin overexpression results in rapidly growing keratinocytic tumors: an in vivo xenograft model of keratoacanthoma.
Billings SD; Southall MD; Li T; Cook PW; Baldridge L; Moores WB; Spandau DF; Foley JG; Travers JB
Am J Pathol; 2003 Dec; 163(6):2451-8. PubMed ID: 14633617
[TBL] [Abstract][Full Text] [Related]
34. T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice.
Gilhar A; David M; Ullmann Y; Berkutski T; Kalish RS
J Invest Dermatol; 1997 Sep; 109(3):283-8. PubMed ID: 9284091
[TBL] [Abstract][Full Text] [Related]
35. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody.
Russell CB; Rand H; Bigler J; Kerkof K; Timour M; Bautista E; Krueger JG; Salinger DH; Welcher AA; Martin DA
J Immunol; 2014 Apr; 192(8):3828-36. PubMed ID: 24646743
[TBL] [Abstract][Full Text] [Related]
36. Grabbing amphiregulin by the tail to better understand keratinocyte growth.
Seykora JT
J Invest Dermatol; 2010 Aug; 130(8):1966-8. PubMed ID: 20631750
[TBL] [Abstract][Full Text] [Related]
37. The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques.
Gordon KB; Bonish BK; Patel T; Leonardi CL; Nickoloff BJ
Br J Dermatol; 2005 Nov; 153(5):945-53. PubMed ID: 16225604
[TBL] [Abstract][Full Text] [Related]
38. Formula PSORI-CM01 eliminates psoriasis by inhibiting the expression of keratinocyte cyclin B2.
Wei JA; Han L; Lu CJ; Zhao RZ; Sun J; Lu Y; Lin HJ
BMC Complement Altern Med; 2016 Jul; 16():255. PubMed ID: 27473420
[TBL] [Abstract][Full Text] [Related]
39. The beneficial effect of blocking Kv1.3 in the psoriasiform SCID mouse model.
Gilhar A; Bergman R; Assay B; Ullmann Y; Etzioni A
J Invest Dermatol; 2011 Jan; 131(1):118-24. PubMed ID: 20739949
[TBL] [Abstract][Full Text] [Related]
40. Avarol inhibits TNF-alpha generation and NF-kappaB activation in human cells and in animal models.
Amigó M; Payá M; Braza-Boïls A; De Rosa S; Terencio MC
Life Sci; 2008 Jan; 82(5-6):256-64. PubMed ID: 18177902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
